Treehill CEO Ali Pashazadeh in Biospace Roundtable
The Gap Is Where The Pain Is: Drug Pricing and Patient Cost
Podcast Episode 1
When it comes to drug pricing, there have been (and are) bad actors in the industry, but the conversation usually ends there. Five KOLs from different parts of the industry came together to discuss the complexities surrounding drug spend and pricing, innovation, funding, and the overall healthcare system – including Treehill Partners CEO Ali Pashazadeh along with Dan Smithey, President, CEO and Co-founder, Serán BioScience; Matthes Price, COO and Co-founder, Promontory Therapeutics; Peter Rubin, Executive Director, No Patient Left Behind; and Rob Williamson, President and COO, Triumvira Immunologics. Lori Ellis, Head of Insights, BioSpace hosted the session which will be available for download in a series of releases.
This first episode explores the drug pricing gap between consumer experience and industry norms. Hear Lori and the KOLs as they explore the drivers of healthcare costs, the CBO, rebates, and overall spend in this new series.